Relapsed/Refractory Hodgkin's Lymphoma Clinical Trial
Official title:
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment
A pilot phase II study with brentuximab vedotin as pre-ASCT induction therapy in relapsed/refractory Hodgkin's lymphoma patients non-responding to IGEV salvage treatment.
Brentuximab vedotin emerged as active single-agent in the treatment of relapsed or refractory
HL.
Some patients don't reach a complete response after salvage treatment with IGEV (ifosfamide,
gemcitabine, vinorelbine) and remain PET positive so the idea is to treat this subset of
patients with brentuximab vedotin with the aim of achieving a complete remission before
transplant.
;